• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series

Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series

Volume 1
Volume 2
Volume 3
Volume 4
Series A: Cardiovascular
Amazon $75
AS $75
AS $75
AS $75
Series A: Cardiovascular
Volume 5:
ALA $115
Volume 6:
ALA $100
Series B: Genomics
AS $75
ALA $125
Series C: Cancer
AS $75
KP $100
Series D: Immunology & Infectious Diseases
AS $75
MS $115
Series E: Patient-Centered Medicine
MS $49
MS $75
AS $75
MS $75

 

UPDATED on 2/16/2020 – Calculations by Joel Shertok, PhD

SUMMARY for BioMed e-Series – Sixteen Volumes Series A:

100% $92,700,000

10% $9,270,000

35% to LPBI

$3,244,500

_________________

Series B:

100% $200,000

10% $20,000

35% to LPBI

$70,000

_________________

Series C:

100% $15,750,000

10% $1,575,000

35% to LPBI

$551,250

_________________

Series D:

100% $23,375,000

10% $2,337,500

35% to LPBI

$818,125

_______________

Series E:

100% $8,180,000

10% $818,000

35% to LPBI

$286,300

 

GRAND TOTAL PROJECTED POTENTIAL REVENUES FROM BioMed e-Series:

$4,970,175

VOL 6 TTL
$100 $515
WORLD-WIDE 180,000
$18,000,000 $92,700,000
$1,800,000 $9,270,000
$630,000 $3,244,500
TTL
$200
10,000
$2,000,000
$200,000
$70,000
TTL
$175
WORLD-WIDE 90,000
$15,750,000
$1,575,000
$551,250
TTL
$190
HEALTHCARE PROFS: VOL 2/3
$23,375,000
$2,337,500
$818,125
TTL
$274
VOL 2, 3, 4
$8,180,000
$818,000
$286,300
TTL: $4,970,175

 

GLOBAL MARKET PENETRATION eBOOKS SERIES A, B, C, D, E
SERIES A CARDIOVASCULAR DISEASE
VOL 1 VOL 2 VOL 3 VOL 4 VOL 5 VOL 6 TTL
PRICE/VOL $75 $75 $75 $75 $115 $100 $515
ASSUME 60,000 CARDIOLOGISTS IN US; 120,000 WORLD-WIDE 180,000
REVENUE = $13,500,000 $13,500,000 $13,500,000 $13,500,000 $20,700,000 $18,000,000 $92,700,000
ASSUME 10% PENETRATION OF MARKET
REVENUE = $1,350,000 $1,350,000 $1,350,000 $1,350,000 $2,070,000 $1,800,000 $9,270,000
ASSUME LPBI SHARE = 35%
REVENUE = $472,500 $472,500 $472,500 $472,500 $724,500 $630,000 $3,244,500
SERIES B GENOMICS
VOL 1 VOL 2 TTL
PRICE/VOL $75 $125 $200
ASSUME 10,000 GENOMIC SPECIALISTS 10,000
REVENUE = $750,000 $1,250,000 $2,000,000
ASSUME 10% PENETRATION OF MARKET
REVENUE = $75,000 $125,000 $200,000
ASSUME LPBI SHARE = 35%
REVENUE = $26,250 $43,750 $70,000
SERIES C CANCER
VOL 1 VOL 2 TTL
PRICE/VOL $75 $100 $175
ASSUME 30,000 ONCOLOGISTS IN US; 60,000 WORLD-WIDE 90,000
REVENUE = $6,750,000 $9,000,000 $15,750,000
ASSUME 10% PENETRATION OF MARKET
REVENUE = $675,000 $900,000 $1,575,000
ASSUME LPBI SHARE = 35%
REVENUE = $236,250 $315,000 $551,250
SERIES D IMMUNOLOGY + INFECTIOUS DISEASES
VOL 1 VOL 2/3 TTL
PRICE/VOL $75 $115 $190
ASSUME 5,000 ONCOLOGISTS IN US – VOL 1 200,000 HEALTHCARE PROFS: VOL 2/3
REVENUE = $375,000 $23,000,000 $23,375,000
ASSUME 10% PENETRATION OF MARKET
REVENUE = $37,500 $2,300,000 $2,337,500
ASSUME LPBI SHARE = 35%
REVENUE = $13,125 $805,000 $818,125
SERIES E PRECISION MEDICINE
VOL 1 VOL 2 VOL 3 VOL 4 TTL
PRICE/VOL $49 $75 $75 $75 $274
ASSUME 20,000 VOL 1 32,000 VOL 2, 3, 4
REVENUE = $980,000 $2,400,000 $2,400,000 $2,400,000 $8,180,000
ASSUME 10% PENETRATION OF MARKET
REVENUE = $98,000 $240,000 $240,000 $240,000 $818,000
ASSUME LPBI SHARE = 35%
REVENUE = $34,300 $84,000 $84,000 $84,000 $286,300
TTL: $4,970,175

 

Same numbers reached by another calculation

 

Assumptions

Worldwide Sale Forecast:

Projected Sales under Assumptions and % Market Penetration

LPBI EBITA: Royalties of 35% vs Amazon’s 65%

UNDER  CONSERVATIVE FORECAST OF 10% Market Penetration

Series A: Cardiovascular Disease

60,000 Cardiologists & Internists practicing Cardiology in the US

&

120,000 Worldwide

IF 100% Penetration in the US THEN

Volumes 1,2,3,4,5,6 60,000 x$515 = $30,900,000

IF 100% Penetration in the Worldwide THEN

120,000 x $515 = $61,800,000

US and WorldWide =

$92,700,000

REALISTIC Penetration of 10% for Series A = $9,270,000

_____________________

LPBI’s share:

$3,244,500 per year

Series B: Genomics

10,000 Genomics

Volume 1:

10,000 x 1 x $75 = $750,000

Volume 2:

10,000  x 1 x $125 = $1,250,000

Total Series B: $2,000,000

REALISTIC penetration of 10% = $200,000

_____________________

LPBI’s share:

$70,000 per year

Series C: Cancer

30,000 Oncologists in the US

60,000 Worldwide

US

Volume 1:

30,000 x 1 x $75 = $2,250,000

+

Volume 2:

30,000 x 1 x $100 = $3,000,000

$5,250,000

+

Worldwide

(60,000 x $175) = $10,500,000

Total Series C: $15,750,000

REALISTIC penetration of 10% = $1,575,000

_____________________

LPBI’s share:

$551,250 per year

Series D: Immunology and Infectious Diseases

5,000 Immunologists &

200,000

Health Care professionals

Volume 1:

[5,000 x 1 x $75 = $375,000]

at REALISTIC 10% penetration = $37,500

+

Volume 2&3:

[200,000 x $115 = $23,000,000]

Total Series D:

$23,375,000

at REALISTIC 10% penetration =

$37,500 + $2,300,000 = $2,337,500

_____________________

LPBI’s share:

$818,125

per year

Series E: Precision Medicine

32,000 Readers

Volumes 2,3.4:

32,000 x 3 x $75 =7,200,000

Volume 1:

20,000 x $49 = 980,000

[assumed Volume 1 had lower readership that Volumes 2,3,4]

= $8,180,000

at REALISTIC penetration of 10% = $818,000

_____________________

LPBI’s share:

$286,300

per year

 

 

 

 

 

 

 

 

 

 

 

SUMMARY for BioMed e-Series – Sixteen Volumes 

Series A:

100% $92,700,000

10% $9,270,000

35% to LPBI

$3,244,500

_________________

Series B:

100% $200,000

10% $20,000

35% to LPBI

$70,000

_________________

Series C:

100% $15,750,000

10% $1,575,000

35% to LPBI

$551,250

_________________

Series D:

100% $23,375,000

10% $2,337,500

35% to LPBI

$818,125

_______________

Series E:

100% $8,180,000

10% $818,000

35% to LPBI

$286,300

 

GRAND TOTAL PROJECTED POTENTIAL REVENUES FROM BioMed e-Series:

$4,970,175

Penetration Levels for Series A,B,C,D,E: The entire BioMed e-Series

IF 10% Penetration >>>>> Total = $14,200,500

[100% Penetration $142,005,000]

Series A: $9,270,000

Series B: $200,000

Series C: $1,575,000

Series D: $2,337,500

Series E: $818,000

LPBI Royalties at 35%

LPBI’s Share for the entire BioMed e-series 16 Volumes: $4,970,175

Of note, for SERIES A: Cardiovascular Diseases – Six volumes:

  • US plus Worldwide penetration rate at 100% has the potential of  $92,700,000 Million !!!!!!!!!!!
  • and at 10% level: $9,270,000 Million !!!!!!!!!!!
  • LPBI Group’s 35% share LPBI’s share for Series A:  $3,244,500 per year

LPBI’s Share for the entire BioMed e-series 16 Volumes: $4,970,175

 

Distribution Schedule of Obligations to Editors and Research Associates
  • Volume Editor(s) = Each 15%;
  • Editor-in-Chief = 15%;
  • Format Translators [AS, KP, MS) = 10%;
  • All Authors per # Words:

= 60% if 1 Editor;

= 45% if 2 Editors;

= 30% if 3 Editors

  • Cost of Sales 35%
 

 

 

Comments:

  • Bundled Series A is $515 [Each e-Book is at $75, Vol. 5 is $115, Vol 6 is $100] on Amazon.com —
  • Assumption was that in the Cardiovascular Diseases e-Series: Each Volume is a Mutual Exclusive Sales Opportunity, however the volumes buyers will buy the entire series as bundled on Amazon for $515.
  • In the US 60,000 Cardiologists and Internists practicing Cardiology
  • In the Entire world 120,000

Assertions:

  • e-Scientific Publishers with Book Distribution Systems like McGraw-Hill, Elsevier, John Wiley could achieve 50% penetration

Disclaimer:

These figures represent a MODEL for an Acquirer of LPBI IP assets — not sales level that LPBI Group can achieve

on our own related to compensations for Authors on Amazon.com under their Prime Membership policies activated

since 2016 regarding the following two Programs which have deleterious effects on book sales and on compensation of

Authors determined by Amazon. The Two Programs are:

  • Book Borrowing
  • Book Page Downloads

For the Acquirer of LPBI’s IP Assets, we will pull out from Amazon all volumes, They will put their LABEL on and

market all the volumes under their label, as done by their own Publishing House.

 

 

Use of LBPI Platform for Educational Purposes

Author: Stephen J. Williams, PhD

 

Goal: to offer supplemental information for student lessons in an upper level Biology course on Cell Signaling and Cell Motility with emphasis on disease etiology including cancer, neurological disease, and cardiovascular disease.

Course: Temple University Department of Biology course Cell Signaling and Motility Spring semester 2019. Forty five students enrolled.

Methodology: Each weekly lesson was presented to students as a PowerPoint presentation. After each lesson the powerpoint presentation was originally meant to be disseminated to each class-registered student on the students Canvas account. Canvas is a cloud based Learning Management Software developed by educational technology company Salt Lake City, Utah company Infrastructure, Inc. According to rough figures, Canvas charges a setup fee and at least $30 per user (for a university the size of Temple University: 55,000 students at $30 each = 1.6 million a semester for user fees only).

As a result of a technical issue with uploading the first week lesson on this system, I had informed the class that, as an alternative means, class presentation notes and lectures will be posted on the site www.pharmaceuticalintelligence.com as a separate post and searchable on all search engines including Google, Twitter, Yahoo, Bing, Facebook etc. In addition, I had informed the students that supplemental information, from curated posts and articles from our site, would be added to the class lecture post as supplemental information they could use for further reading on the material as well as helpful information and reference for class projects.

The posted material was tagged with #TUBiol3373 (university abbreviation, department, course number) and disseminated to various social media platforms using our system. This allowed the students to enter #TUBiol3373 in any search engine to easily find their lecture notes and supplemental information.

This gave students access to lectures on a mobile platform which was easily discoverable due to our ability to do search engine optimization. (#TUBiol3373 was among the first search results on most popular search engines).

 

Results (ongoing): After the first week, all 45 students used LBPI platform to access these lecture notes with 17 out of 45 continuing to refer to the site during every week (week 1-4) to the class notes. This was evident from our site statistics as well as number of downloads of the material. The students had used the #TUBIol3373 and were directed to the site mainly from search engines Google and Yahoo. In addition, students had also clicked on the links corresponding to supplemental information which I had included, from articles on our site. In addition, because of the ability to incorporate media on our site, additional information including instructional videos and interviews were included in lecture posts, and this material was easily updated on the instructor’s side.

Adoption of the additional material from our site was outstanding, as many students had verbally said that the additional material was very useful in their studies. This was also evidenced by site statistics owing to the secondary clicks made from the class lecture post going to additional articles, some not even included as links on the original post.

In addition, and more important, students had incorporated many of the information from the additional site articles posted and referenced in their class group projects. At end of semester a survey will be provided to assess the usefulness of such a teaching strategy.

From a technical standpoint, the ease at which posts of this nature can be made as well as the ease of including links to full articles as references as well as media has been noted. Although students seem to navigate the Canvas software with ease, they had noticed many professors have issues or problems with using this software, especially with navigating the software for their needs.   LBPI’s platform is an easily updated, accessible, and extensive knowledge system which can alleviate many of these technical issues and provide the added value of incorporating media based instructional material as well as downloadable file and allow the instructor ability to expound on the presented material with commentary. In addition due to the social nature of the platform, feedback can be attained by use of curated site statistics and commentary sections as well as online surveys.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 1,979 other subscribers

  • Recent Posts

    • Omecamtiv mecarbil – A study examined efficacy and tolerability in Heart Failure patients with SBP ≤100 mmHg enrolled in GALACTIC-HF May 23, 2022
    • Sperm epigenetic clock and pregnancy outcomes May 14, 2022
    • Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare May 9, 2022
    • Relevance of Twitter.com forthcoming Payment System for Scientific Content Promotion and Monetization May 9, 2022
    • Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and all Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON May 7, 2022
    • Data Science: Step by Step – A Resource for LPBI Group’s One-Year Internship in IT, IS, DS May 7, 2022
    • 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON May 1, 2022
    • We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022 April 25, 2022
    • The durability of T cells versus the triggered of high levels of antibodies: Rationale for the development of T cells focused vaccines   April 22, 2022
    • The Framingham Study: Across 6 Decades, Cardiovascular Disease Among Middle-Aged Adults – mean life expectancy increased and the RLR of ASCVD decreased. Effective primary prevention efforts and better screening increased. April 22, 2022
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 Rosalind Codrington, PhD
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
%d bloggers like this: